CTLA4 and neoplasm: They show that both local and systemic administration of the CTLA-4-STAT3 AsiC drastically reduced tumor associated regulatory T lymphocytes (Tregs) in various tumor models, as well as a potent inhibition of tumor growth and metastasis [65].